FI3511004T3 - Yhdistelmävalmisteita syövän hoitoon - Google Patents
Yhdistelmävalmisteita syövän hoitoon Download PDFInfo
- Publication number
- FI3511004T3 FI3511004T3 FIEP19158672.6T FI19158672T FI3511004T3 FI 3511004 T3 FI3511004 T3 FI 3511004T3 FI 19158672 T FI19158672 T FI 19158672T FI 3511004 T3 FI3511004 T3 FI 3511004T3
- Authority
- FI
- Finland
- Prior art keywords
- lag
- protein
- derivative
- antineoplastic agent
- amino acid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 13
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 102000017578 LAG3 Human genes 0.000 claims 32
- 101150030213 Lag3 gene Proteins 0.000 claims 32
- 229940034982 antineoplastic agent Drugs 0.000 claims 22
- 239000002246 antineoplastic agent Substances 0.000 claims 22
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 20
- 150000001413 amino acids Chemical class 0.000 claims 16
- 229910052697 platinum Inorganic materials 0.000 claims 10
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 8
- 229940056913 eftilagimod alfa Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 108020001580 protein domains Proteins 0.000 claims 6
- 101710183280 Topoisomerase Proteins 0.000 claims 5
- 229960004562 carboplatin Drugs 0.000 claims 5
- 190000008236 carboplatin Chemical compound 0.000 claims 5
- 229960001756 oxaliplatin Drugs 0.000 claims 5
- 102000043131 MHC class II family Human genes 0.000 claims 4
- 108091054438 MHC class II family Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229960000303 topotecan Drugs 0.000 claims 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 229950007221 nedaplatin Drugs 0.000 claims 2
- 190000005734 nedaplatin Chemical compound 0.000 claims 2
- 229950005566 picoplatin Drugs 0.000 claims 2
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims 2
- 229960005399 satraplatin Drugs 0.000 claims 2
- 190014017285 satraplatin Chemical compound 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322626.1A GB201322626D0 (en) | 2013-12-19 | 2013-12-19 | Combined preparations for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3511004T3 true FI3511004T3 (fi) | 2024-09-25 |
Family
ID=50071175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19158672.6T FI3511004T3 (fi) | 2013-12-19 | 2014-12-19 | Yhdistelmävalmisteita syövän hoitoon |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10736940B2 (enExample) |
| EP (3) | EP3089749B1 (enExample) |
| JP (2) | JP6691054B2 (enExample) |
| KR (3) | KR20160093076A (enExample) |
| CN (2) | CN112957452A (enExample) |
| AU (1) | AU2014368420B2 (enExample) |
| DK (2) | DK3511004T3 (enExample) |
| ES (2) | ES2730976T3 (enExample) |
| FI (1) | FI3511004T3 (enExample) |
| GB (1) | GB201322626D0 (enExample) |
| PL (2) | PL3089749T3 (enExample) |
| PT (2) | PT3511004T (enExample) |
| TR (1) | TR201910866T4 (enExample) |
| WO (1) | WO2015091970A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| US10265379B2 (en) * | 2015-09-16 | 2019-04-23 | Annabelle Rodriguez Oquendo | Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| BR112018012352A2 (pt) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anticorpos anti-lag3 e fragmentos de ligação ao antígeno |
| CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| WO2021242876A1 (en) * | 2020-05-27 | 2021-12-02 | Agilent Technologies, Inc. | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) |
| EP4157313A1 (en) * | 2020-05-28 | 2023-04-05 | Immutep S.A.S. | Treatment of cancer |
| AU2022298240A1 (en) * | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
| US5098702A (en) | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| CA1341281C (en) | 1986-07-09 | 2001-08-07 | Hubert J.P. Schoemaker | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| DE69020143T2 (de) | 1989-02-17 | 1996-01-25 | Chiron Mimotopes Pty Ltd | Verfahren zur verwendung und herstellung von peptiden. |
| JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規ｄｎａならびにそれを含有する発現プラスミド |
| US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
| FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| US7294712B2 (en) | 1990-06-04 | 2007-11-13 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| DE69114299T3 (de) | 1990-09-14 | 2005-09-15 | The Johns Hopkins University | Verfahren und zusammensetzungen für gentherapie und stärkung des immunsystems. |
| JP3459268B2 (ja) | 1990-09-17 | 2003-10-20 | 中外製薬株式会社 | 抗癌剤 |
| US6596536B1 (en) | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
| ATE504650T1 (de) | 1991-02-08 | 2011-04-15 | Aventis Pharma Sa | Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen |
| WO1992013950A2 (fr) | 1991-02-12 | 1992-08-20 | Roussel-Uclaf | SEQUENCES NUCLEOTIDIQUES CODANT POUR DES REGIONS VARIABLES DE CHAINES β DES RECEPTEURS DES LYMPHOCYTES T HUMAINS, SEGMENTS PEPTIDIQUES CORRESPONDANTS ET LES APPLICATIONS DIAGNOSTIQUES ET THERAPEUTIQUES |
| US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
| US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
| US6506604B2 (en) | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| JP3700859B2 (ja) | 1994-05-06 | 2005-09-28 | アンスティテュ ギュスタブ ルシ | Ｌａｇ−３タンパク質の可溶性ポリペプチドフラクション；製造方法、治療用製剤、抗イディオタイプ抗体 |
| US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
| US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| US6482925B1 (en) | 1996-11-28 | 2002-11-19 | Applied Research Systems Ars Holding N.V. | Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants |
| DE69632967T2 (de) | 1996-11-29 | 2005-08-11 | Applied Research Systems Ars Holding N.V. | Verfahren zur Verhinderung der Transplantabstoßung bei einer Transplantation und zur Herstellung einer universalen Gentherapie-Wirtszelle unter Anwendung von Lymphocyten-Aktivierungsgen (LAG-3) |
| EP1007637B1 (en) | 1997-04-14 | 2004-06-30 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant aav product |
| EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
| US6037177A (en) | 1997-08-08 | 2000-03-14 | Cell Genesys, Inc. | Method for increasing the efficiency of recombinant AAV production |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ATE264911T1 (de) | 1998-02-02 | 2004-05-15 | Univ Johns Hopkins Med | Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen |
| FR2777890B1 (fr) | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
| AU5458500A (en) | 1999-06-02 | 2000-12-18 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
| FR2795415B1 (fr) | 1999-06-28 | 2003-09-05 | Roussy Inst Gustave | Compose peptidique derive d'une orf decalee du gene ice |
| AT409086B (de) | 1999-11-16 | 2002-05-27 | Igeneon Krebs Immuntherapie | Neue verwendung von antikörpern als impfstoffe |
| AU2001258476A1 (en) | 2000-04-26 | 2001-11-07 | Biovector Therapeutics | Use of particulate vectors in immunomodulation |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| ATE519779T1 (de) | 2001-09-19 | 2011-08-15 | Roussy Inst Gustave | An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen |
| DK1505973T3 (da) | 2002-05-17 | 2010-05-31 | Celgene Corp | Kombinationer til behandling af multipelt myelom |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| WO2005035779A2 (en) | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc | Method |
| FR2868781B1 (fr) | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
| JP2006124383A (ja) | 2004-09-30 | 2006-05-18 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
| JP2006141346A (ja) | 2004-11-24 | 2006-06-08 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
| US7964571B2 (en) * | 2004-12-09 | 2011-06-21 | Egen, Inc. | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| US20070231298A1 (en) | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| WO2009032256A2 (en) * | 2007-08-30 | 2009-03-12 | Cell Genesys, Inc. | Apc activators in combination with a cytokine-secreting cell and methods of use thereof |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2011339929B2 (en) * | 2010-12-06 | 2017-05-11 | Tom C. Tsang | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
| WO2012135408A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| AU2013216320A1 (en) | 2012-02-01 | 2014-04-03 | Compugen Ltd. | C10RF32 antibodies, and uses thereof for treatment of cancer |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| WO2015131176A1 (en) | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
-
2013
- 2013-12-19 GB GBGB1322626.1A patent/GB201322626D0/en not_active Ceased
-
2014
- 2014-12-19 CN CN202110293412.9A patent/CN112957452A/zh active Pending
- 2014-12-19 EP EP14830806.7A patent/EP3089749B1/en active Active
- 2014-12-19 TR TR2019/10866T patent/TR201910866T4/tr unknown
- 2014-12-19 EP EP19158672.6A patent/EP3511004B1/en active Active
- 2014-12-19 KR KR1020167019272A patent/KR20160093076A/ko not_active Ceased
- 2014-12-19 DK DK19158672.6T patent/DK3511004T3/da active
- 2014-12-19 FI FIEP19158672.6T patent/FI3511004T3/fi active
- 2014-12-19 JP JP2016559686A patent/JP6691054B2/ja active Active
- 2014-12-19 PL PL14830806T patent/PL3089749T3/pl unknown
- 2014-12-19 ES ES14830806T patent/ES2730976T3/es active Active
- 2014-12-19 KR KR1020227025903A patent/KR102593917B1/ko active Active
- 2014-12-19 PT PT191586726T patent/PT3511004T/pt unknown
- 2014-12-19 ES ES19158672T patent/ES2986949T3/es active Active
- 2014-12-19 KR KR1020227014127A patent/KR102441425B1/ko active Active
- 2014-12-19 US US15/105,789 patent/US10736940B2/en active Active
- 2014-12-19 EP EP24178618.5A patent/EP4414035A3/en active Pending
- 2014-12-19 WO PCT/EP2014/078779 patent/WO2015091970A1/en not_active Ceased
- 2014-12-19 DK DK14830806.7T patent/DK3089749T3/da active
- 2014-12-19 CN CN201480073584.3A patent/CN105916504B/zh active Active
- 2014-12-19 PT PT14830806T patent/PT3089749T/pt unknown
- 2014-12-19 AU AU2014368420A patent/AU2014368420B2/en active Active
- 2014-12-19 PL PL19158672.6T patent/PL3511004T3/pl unknown
-
2019
- 2019-09-09 JP JP2019163672A patent/JP7160345B2/ja active Active
-
2020
- 2020-07-01 US US16/918,527 patent/US12214012B2/en active Active
-
2024
- 2024-12-24 US US19/000,820 patent/US20250127856A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015518818A5 (enExample) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| JP2015517488A5 (enExample) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2017503014A5 (enExample) | ||
| MY201382A (en) | Pde9 inhibitor and use thereof | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2016530280A5 (enExample) | ||
| JP2019203035A5 (enExample) | ||
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BR112016012506A8 (pt) | combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
| BR112015009280A2 (pt) | preparações liofilizadas de melfalana flufenamida | |
| CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2013542196A5 (enExample) | ||
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |